What is Spruce Biosciences, Inc. (SPRB) stock price today?

Spruce Biosciences, Inc. (SPRB) is currently trading at $39.65, down 4.39% today.

What is SPRB P/E ratio?

Spruce Biosciences, Inc.'s P/E ratio is -1.12. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is SPRB return on equity (ROE)?

Spruce Biosciences, Inc.'s return on equity (ROE) is -123.53%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Spruce Biosciences, Inc.'s market cap?

Spruce Biosciences, Inc. has a market capitalization of $113.95M.

NASDAQ · Biotechnology

Spruce Biosciences, Inc. (SPRB) Stock

$39.65 -4.39% NASDAQ: SPRB Healthcare

Valuation

Metric	Value
Price	$39.65
Market Cap	$113.95M
P/E Ratio	-1.12
P/B Ratio	1.33
P/S Ratio	0.00
EPS (TTM)	$-50.83
52-Week High	$240.00
52-Week Low	$7.88
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-123.53%
ROA	-49.93%
ROCE	-52.05%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.09
Current Ratio	5.20

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$10.0M	$5.0M	$0
Operating Profit	$-42.0M	$-47.0M	$-52.0M	$-56.0M	$-37.0M
Net Profit	$-42.0M	$-46.0M	$-48.0M	$-53.0M	$-39.0M
EPS	$-68.25	$-72.00	$-93.00	$-96.75	$-50.83
Op Margin	—	—	-515.3%	-1143.4%	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$126.0M	$86.0M	$104.0M	$45.0M	$53.0M
Total Liabilities	$15.0M	$17.0M	$27.0M	$16.0M	$11.0M
Cash	$43.0M	$24.0M	$96.0M	$39.0M	$49.0M
Borrowings	$7.0M	$6.0M	$5.0M	$3.0M	$1.0M

Latest News

American Express, Biogen upgraded: Wall Street's top analyst calls The Fly · Jul 13, 2026 B. Riley Initiates Spruce Biosciences at Buy With $160 Price Target MT Newswires · Jul 13, 2026 Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit Business Wire · Jul 8, 2026 Spruce Biosciences Joins the Russell 3000® Index Business Wire · Jun 29, 2026 Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs Business Wire · Jun 22, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-36.0M	$-42.0M	$-33.0M	$-56.0M	$-33.0M
Investing Cash Flow	$-79.0M	$24.0M	$56.0M	$0	$0
Financing Cash Flow	$0	$0	$-3.0M	$0	$-5.0M
Net Cash Flow	$-114.0M	$-18.0M	$72.0M	$-58.0M	$10.0M
Free Cash Flow	$-36.0M	$-42.0M	$-33.0M	$-56.0M	$-33.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.02
EV / EBITDA	-0.76
FCF Yield	-34.00%
Quick Ratio	9.23
Interest Coverage	-26.63
Return 1Y	-91.62%
Return 3Y	-99.61%
Return 5Y	-99.92%

Ownership

Insiders Held3.52%

Institutions Held32.09%

Institutions Float Held33.27%

Institutional Holder	Shares	Report Date
Ikarian Capital, LLC	121,356	2026-03-31
Millennium Management Llc	111,888	2026-03-31
Citadel Advisors Llc	69,999	2026-03-31
Adar1 Capital Management, LLC	58,600	2026-03-31
Alyeska Investment Group, L.p.	51,671	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
COEPCoeptis Therapeutics Holdings, Inc.	$10.99	-8.57%	-4.45	$38.62M	0.00%
CUECue Biopharma, Inc.	$16.71	-10.50%	-0.95	$121.39M	0.00%
EQEquillium, Inc.	$1.19	-9.85%	-5.50	$75.46M	0.00%
HOWLWerewolf Therapeutics, Inc.	$0.98	-1.71%	-1.26	$47.63M	0.00%
IOBTIO Biotech, Inc.	$0.01	-27.59%	-0.01	$885690	0.00%

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc. is led by CEO Javier Szwarcberg, employs 20 people, headquartered in US, publicly traded since 2020.

Spruce Biosciences, Inc. (SPRB) stock trades at $39.65 with a market capitalization of $113.95M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.12, reflecting a net loss over the last twelve months, price-to-book of 1.33, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.88 and $240.00, and currently trades 83.5% below its 52-week high.

On profitability, Spruce Biosciences, Inc. generates a return on equity (ROE) of -123.53% (negative, reflecting a net loss), return on capital employed of -52.05%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.